BMRN BIOMARIN PHARMACEUTICAL INC revenue, earnings and financials

For the quarter ended June 30, 2026, BIOMARIN PHARMACEUTICAL INC reported revenue of $990M (up 19.9% from a year earlier), net income of $44.8M and diluted EPS of $0.23; over the last four quarters revenue was $3.41B and net income $73.0M; for the fiscal year ended December 2025 revenue was $3.22B, up 12.9% on the year before.

BMRN annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $3.22B, gross profit n/a, operating income $409M, net income $349M (margin 10.8%), EPS $1.80
• Fiscal year ended Dec 2024: revenue $2.85B, gross profit n/a, operating income $484M, net income $427M (margin 15.0%), EPS $2.21
• Fiscal year ended Dec 2023: revenue $2.42B, gross profit n/a, operating income $186M, net income $168M (margin 6.9%), EPS $0.87
• Fiscal year ended Dec 2022: revenue $2.10B, gross profit n/a, operating income $161M, net income $142M (margin 6.8%), EPS $0.75
• Fiscal year ended Dec 2021: revenue $1.85B, gross profit n/a, operating income −$82.3M, net income −$64.1M (margin -3.5%), EPS −$0.35

BMRN quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $990M (up 19.9% year over year), net income $44.8M, EPS $0.23
• Quarter ended Mar 31, 2026: revenue $766M (up 2.8% year over year), net income $106M, EPS $0.54
• Quarter ended Dec 31, 2025 (from the annual report): revenue $875M (up 17.0% year over year), net income −$46.6M, EPS −$0.22
• Quarter ended Sep 30, 2025: revenue $776M (up 4.1% year over year), net income −$30.7M, EPS −$0.16
• Quarter ended Jun 30, 2025: revenue $825M (up 15.9% year over year), net income $241M, EPS $1.23
• Quarter ended Mar 31, 2025: revenue $745M (up 14.8% year over year), net income $186M, EPS $0.95
• Quarter ended Dec 31, 2024 (from the annual report): revenue $747M (up 15.6% year over year), net income $125M, EPS $0.65
• Quarter ended Sep 30, 2024: revenue $746M (up 28.3% year over year), net income $106M, EPS $0.55
• Quarter ended Jun 30, 2024: revenue $712M (up 19.6% year over year), net income $107M, EPS $0.55
• Quarter ended Mar 31, 2024: revenue $649M (up 8.8% year over year), net income $88.7M, EPS $0.46
• Quarter ended Dec 31, 2023 (from the annual report): revenue $646M (up 20.2% year over year), net income $20.3M, EPS $0.10
• Quarter ended Sep 30, 2023: revenue $581M (up 15.0% year over year), net income $40.4M, EPS $0.21
• Quarter ended Jun 30, 2023: revenue $595M (up 11.5% year over year), net income $56.0M, EPS $0.29
• Quarter ended Mar 31, 2023: revenue $596M (up 14.8% year over year), net income $50.9M, EPS $0.27
• Quarter ended Dec 31, 2022 (from the annual report): revenue $538M (up 19.5% year over year), net income −$210K, EPS $0.01
• Quarter ended Sep 30, 2022: revenue $505M (up 23.6% year over year), net income −$6.65M, EPS −$0.04
• Quarter ended Jun 30, 2022: revenue $534M (up 6.4% year over year), net income $27.7M, EPS $0.15
• Quarter ended Mar 31, 2022: revenue $519M (up 6.9% year over year), net income $121M, EPS $0.63
• Quarter ended Dec 31, 2021 (from the annual report): revenue $450M, net income −$57.9M, EPS −$0.31
• Quarter ended Sep 30, 2021: revenue $409M, net income −$36.5M, EPS −$0.20

BMRN cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $828M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow $573M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow $159M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow $176M, share buybacks $0
• Fiscal year ended Dec 2021: operating cash flow $305M, share buybacks $0

BMRN balance sheet

• Jun 30, 2026: cash $874M, total assets $11.7B, total liabilities $5.40B, shareholders' equity $6.32B, long-term debt $3.53B
• Mar 31, 2026: cash $2.22B, total assets $8.59B, total liabilities $2.38B, shareholders' equity $6.21B
• Dec 31, 2025: cash $1.31B, total assets $7.59B, total liabilities $1.51B, shareholders' equity $6.09B, long-term debt $597M
• Sep 30, 2025: cash $1.25B, total assets $7.61B, total liabilities $1.56B, shareholders' equity $6.06B
• Jun 30, 2025: cash $1.21B, total assets $7.46B, total liabilities $1.43B, shareholders' equity $6.03B
• Mar 31, 2025: cash $1.05B, total assets $7.15B, total liabilities $1.35B, shareholders' equity $5.79B
• Dec 31, 2024: cash $943M, total assets $6.99B, total liabilities $1.33B, shareholders' equity $5.66B
• Sep 30, 2024: cash $675M, total assets $6.85B, total liabilities $1.44B, shareholders' equity $5.41B

What is BMRN's revenue?

BIOMARIN PHARMACEUTICAL INC reported $3.41B of revenue over its last four quarters, through June 30, 2026.

Is BMRN profitable?

Yes. BIOMARIN PHARMACEUTICAL INC earned $73.0M over the last four quarters.

What is BMRN's EPS?

Diluted earnings per share over the last four quarters were $0.39; $0.23 in the latest quarter.

BMRN ownership and insider trades · All stocks